Cure Duchenne®

2026

Impact Report

Dear Friends,

When our son Hawken was diagnosed with Duchenne muscular dystrophy more than two decades ago, the future felt uncertain. There were no approved therapies, no clinical trials, and little hope offered to families like ours. But we refused to accept that future, and **you have walked beside us ever since.**

Thanks to your generosity, what once felt impossible is now taking shape. In 2025, several therapies we funded years ago moved closer to FDA approval. These are now poised to become the **next generation of Duchenne treatments,** building on early approvals that validated the science. Your investment, commitment, and belief in progress made this possible.

But science cannot stand alone. Breakthroughs in the lab must be matched by expert delivery in the real world. That is why CureDuchenne continues to **expand care alongside research.** In 2025, we opened our second CureDuchenne Clinic within the Neuromuscular Program at Rady Children's Health Orange County. This clinic is providing next-generation therapies, bilingual family support, and comprehensive care to families across Southern California.

This was also the year **Duchenne was added to the U.S. Recommended Uniform Screening Panel for newborns.** Now, babies across the country can be diagnosed before symptoms appear and receive care when treatments are believed to be most effective.

These are landmark achievements. **But we are not finished.** Today's treatments still fall short of a cure. Too many individuals are excluded based on age, mutation, or stage of disease. And too many families still lack access to expert care.

We must do more to ensure that **every person with Duchenne has a real chance at treatment.** That is why, in 2025, we funded Entos Pharmaceuticals. Their non-viral, redosable gene therapy platform could potentially overcome current barriers in Duchenne gene therapy and perhaps treat all individuals with Duchenne. This is just one example of how your support is driving new approaches forward.

As you read this year's Impact Report, we hope you see your role in every breakthrough, every clinic, and every family that now has more hope than before. **Your partnership is turning promise into progress.**

Let's keep going. **Because every child deserves the chance to grow up.**

DEBRA & PAUL MILLER
Co-Founders, CureDuchenne

Our Mission

We are committed to improving the lives of everyone affected by Duchenne through accelerating research to find the cure, improving care and empowering the Duchenne community.

2026 BOARD OF DIRECTORS

FOUNDERS

Debra Miller
Founder and Chief Executive Officer, CureDuchenne

Paul Miller
President and Chief Operating Officer, PMG, and Founder, CureDuchenne

CHAIRPERSON

Jeffrey Goffman
Partner, Webster Equity Partners

BOARD

Chris Finazzo
Chief Commercial Officer, SeaWorld Entertainment

David MacInnis
Financial Services Professional and Philanthropist

Nicholas Prytherch, Ed.D.
Managing Partner, MLP Government Affairs

Peter Strelow
Co-Chief Operations Officer and Chair of the PIMCO Funds

Tim Sullivan
Founder and former Chief Executive, Officer of ActivePDF, Inc., and Philanthropist

Ryan Williams
Partner, Athletes First

Understanding Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is a progressive muscle-wasting neuromuscular disease. It is the most common and severe form of muscular dystrophy, affecting approximately 1 in every 5,000 male births.

The root cause of Duchenne is genetic mutations that affect the production of dystrophin, a vital muscle protein integral to maintaining muscle health. The absence of dystrophin leads to muscle cell damage and death, starting in the skeletal muscle and eventually leading to heart and respiratory failure.

Children with Duchenne experience significant delays in achieving early developmental milestones, and then progressively lose functions. By the age of 10 to 12, the majority will need a wheelchair for mobility. As they transition into late adolescence, their cardiac and respiratory muscles become severely compromised. Tragically, many individuals with Duchenne do not live past their late twenties.

This disorder is indiscriminate, affecting individuals across all cultural, economic, and social divides.

5

Typically, individuals are diagnosed around 5 years old

12

Most lose the ability to walk before their teenage years

20

Most don't survive beyond their mid-20s

Cure Duchenne®

- Dystrophin abnormalities
- Possible learning and cognitive difficulties

- Decreased heart function
- Cardiomyopathy
- Leads to heart failure

- Weakens diaphragm
- Requires ventilator
- Leads to pneumonia

- Loss of muscle mass
- Weakness
- Inflammation
- Fibrosis

- Brittle and weak

Accelerating the Cure

Venture Philanthropy: A Model of Innovation

CureDuchenne Ventures enables development of new therapies by identifying the most promising research opportunities and providing critical early-stage funding. But we don't just write checks. We provide strategic guidance, connect researchers with expertise, and help position companies for success.

Where We Go, Funding Follows

When CureDuchenne invests in a company, it validates the science and attracts much larger investments to these companies, from venture capital firms and pharmaceutical companies.

This model is also sustainable because when our investments succeed, we reinvest 100% of returns into research and programs. Your donation doesn't just fund one project—it creates a perpetual cycle of innovation.

But venture success takes time. Most of our 2025 breakthroughs came from investments made 5-10 years ago. The therapies that will help patients in the future need funding today.

A Complete Toolkit for a Complex Disease

Because Duchenne is a severe and complex disease, with more than 7,000 known genetic mutations and wide variability in how the disease progresses, the treatments available today do not do enough to stop Duchenne in its tracks and are not available to everyone. Thus, the future depends on building a toolkit of therapies that are more effective, accessible to more individuals, and can be combined for addressing all aspects of the disease. CureDuchenne is working to expand that toolkit by funding diverse, complementary approaches, like gene therapy, exon skipping, muscle stabilizers, cardiac treatments, and more, so that every person with Duchenne has a path forward, no matter their age, mutation, or stage of disease.

OUR IMPACT

$27M
Invested in 51 different research projects

$4.6B+
Follow-on funding attracted to those companies

$1 → $170
For every $1 CureDuchenne invests, biotech and pharma companies invest $170 more

3
Drugs pursuing FDA approval in 2026 were directly supported by CureDuchenne

$12B
CureDuchenne-backed company (invested in 2018) now in process of $12B acquisition by Novartis

The Ventures Team

Michael G. Kelly, Ph.D.
Chief Scientific Officer

Lianna R. Orlando, Ph.D.
Vice President of Research

Po-Ting Liu, Ph.D.
Principal

CureDuchenne's Investment Timeline

Our portfolio includes a range of early-stage companies that are exploring innovative approaches to treating Duchenne muscular dystrophy. These investments are crucial in supporting the foundational research that can lead to significant breakthroughs. It also includes public companies advancing both early and late-stage clinical trials in gene therapy, next-generation exon skipping and regenerative medicine approaches that are anticipated to receive approval in the coming years.



FROM RESEARCH TO TREATMENTS

2025 Breakthroughs

2025 marked a transformative year for CureDuchenne Ventures' portfolio. Companies we funded years ago delivered groundbreaking clinical data that brings them closer to FDA approval. New investments positioned next-generation therapies for future success. And the direct line from research investment to therapeutic progress is clearer than ever.

NEW INVESTMENT

entos Pharmaceuticals

CureDuchenne Funded: May 2025
Investment: $1M

CureDuchenne committed $1 million to Entos Pharmaceuticals to advance a non-viral, redosable, gene therapy platform for delivering full-length dystrophin for Duchenne, addressing major limitations of current AAV-based approaches. Today's gene therapies exclude patients with pre-existing AAV immunity, may wear off, cannot be redosed, and deliver only shortened versions of the dystrophin gene. Entos' Fusogenix PLV platform may overcome these challenges and potentially be safer and less expensive than current approaches. If successful, this breakthrough could allow for more effective therapies, expand access, and bring us closer to a future where gene therapy is a flexible, lifelong tool in the fight against Duchenne.

"CureDuchenne's funding and advice has been essential to advancing our technology platform for use in Duchenne muscular dystrophy. This is a potential game changer for people with Duchenne, and also for our company."

—John Lewis, Founder and Chief Executive Officer, Entos Pharmaceuticals

CLINICAL PROGRESS UPDATES

Capricor Therapeutics™

CureDuchenne Funded: 2015
2025 Update: Positive Phase 3 Data; Under Review for FDA Approval

Capricor announced positive Phase 3 results for deramiocel, achieving statistically significant improvements in both upper-limb function and cardiac output. Deramiocel is currently under review for FDA approval, and if successful could be a first-in-class treatment for Duchenne-related heart disease, the leading cause of death in Duchenne. CureDuchenne's early investment in 2015 helped propel this program at an early, critical stage, demonstrating the long-term impact of early funding.

AVIDITY® BIOSCIENCES

CureDuchenne Funded: 2018
2025 Update: Positive Exon 44 Skipping Trial Data; Approaching FDA Submission

Avidity Biosciences reported positive clinical results for del-zota, an exon 44 skipping therapy that could benefit about 6% of individuals with Duchenne. The EXPLORE44 trial showed significant results, with increases in total dystrophin up to 25%, reduction in creatine kinase to near normal levels, and functional improvements in multiple measures after one year of treatment. CureDuchenne's 2018 investment helped advance this next-generation approach, which is now on track for FDA submission in 2026. In the meantime, Avidity is making del-zota available to anyone who is amenable to skipping exon 44 at no cost via a Managed Access Program. Novartis has also decided to acquire Avidity, citing the strength of the programs targeting Duchenne and other neuromuscular diseases, which is further validation of CureDuchenne's decision to fund early on.

Dyne™ THERAPEUTICS

CureDuchenne Funded: 2020
2025 Update: Positive Data from Exon 51 Skipping Trial; Approaching FDA Submission

Dyne Therapeutics announced that skipping exon 51 with z-rostudirsen in a registrational expansion cohort met its primary endpoint – a statistically significant increase in dystrophin at 6 months—and was associated with functional improvements in multiple measurements. Long-term results (out to 24 months) from the earlier cohorts show that all the functional improvements are sustained. CureDuchenne's 2020 investment helped advance this program from early research to a therapy now being prepared for FDA accelerated approval. It is estimated that up to 13% of individuals with Duchenne have mutations that could benefit by skipping exon 51.

Edgewise THERAPEUTICS

CureDuchenne Funded: 2019
2025 Update: Positive Results in both Duchenne and Becker

Edgewise Therapeutics is developing a first-in-class muscle-stabilizing therapy, sevastemten, for potential use in both Duchenne and Becker muscular dystrophy. Sevasemten works by protecting muscle fibers from damage regardless of genetic mutation, offering potential benefit to all individuals with either disease. In Becker, Edgewise has reported positive data from the open label extension trial, and data from the pivotal trial is expected in 2026. If approved, this would be the first therapy for Becker muscular dystrophy, addressing a critical unmet need. In Duchenne, Edgewise reported encouraging functional measures and are now moving forward with a pivotal trial.

Investing in Tomorrow's Therapies

The breakthroughs of 2025 highlight that even when CureDuchenne Ventures has invested wisely, early-stage investments can have long timelines, as therapies funded five to ten years ago are just now nearing FDA approval. Together, the diverse approaches in Duchenne are building a comprehensive, combinable toolkit to fight Duchenne from every angle. But progress only continues if the funding does. The next wave of therapies, which we hope will do more to stop the disease in its tracks, needs support now to reach patients in the next decade.

The Power of Early Diagnosis

A Historic Milestone

For two decades, researchers and clinicians have worked toward earlier diagnosis of Duchenne, yet the average age of diagnosis has remained around four years old. In 2025, the U.S. Department of Health and Human Services added Duchenne muscular dystrophy to the Recommended Uniform Screening Panel (RUSP) for newborn screening. This change will pave the way for more states to adopt universal newborn screening for Duchenne, and it reflects years of collaboration, research, and advocacy across the Duchenne community.

Why It Matters

This decision marks a pivotal step because earlier diagnosis offers families a better chance to preserve function, avoid delays, and begin care and treatment when it may be most effective. As the pipeline of potential treatments for Duchenne grows, identifying individuals as early as possible becomes even more essential.

CureDuchenne's Role

Several pilot newborn screening programs, including a study at Brigham and Women's Hospital supported by CureDuchenne, were instrumental in showing that Duchenne screening can be implemented effectively and that the diagnostic tools are working.

Nationwide Implementation

Some states have already implemented newborn screening for Duchenne and others are in the process of approving or implementing it. While timelines vary by state, inclusion on the RUSP is expected to encourage broader adoption of Duchenne screening programs nationwide.

Redefining Care

From Research to Clinical Excellence

Groundbreaking therapies only change lives if they're delivered with expertise and compassion. As individuals with Duchenne live longer and their needs evolve, healthcare must keep pace. This is why CureDuchenne invests not just in research, but in the entire care ecosystem: educating families, training professionals, and ensuring every individual receives the highest standard of care. Research creates options. Clinical excellence delivers them.

Welcoming a Leader in Duchenne Care

CureDuchenne is proud to welcome Dr. Brenda Wong as Chief Medical Advisor, effective January 2026. A nationally recognized leader in neuromuscular medicine, Dr. Wong brings over 45 years of experience, including leading 20+ clinical trials and building top-tier care centers at Cincinnati Children's Hospital and UMass Memorial Medical Center. Dr. Wong will guide CureDuchenne's clinical strategy, ensuring programs meet the highest standards of care while advising industry partners on trial design that reflects real patient needs.

The CureDuchenne Cares Program

CureDuchenne Cares is our interactive education and outreach program serving parents, caregivers, physical therapists, and allied health professionals dedicated to supporting patients with Duchenne and Becker muscular dystrophy. For more than 20 years, we've provided comprehensive resources, information, and best practices to improve quality of life.

2025 IMPACT

1,448
Individuals attended CureDuchenne conferences, workshops, dinner sessions and webinars

224
Patients with Duchenne and Becker muscular dystrophy served at CureDuchenne Clinics

91
1:1 sessions providing personalized, unbiased guidance from CureDuchenne scientists, physical therapists, etc.

"The CureDuchenne FUTURES Conference was just what the doctor ordered. We built old and new friendships, learned about new advances in the Duchenne world, and gained valuable insights on how to care for our son better."

—Laura Preece, mother of 11-year-old Baylen

Leading the Way in Training Care Professionals

Physical and occupational therapists trained specifically in Duchenne care can dramatically improve outcomes, helping patients maintain mobility, strength, and independence longer. That's why CureDuchenne created the only Duchenne-specific PT/OT certification program in the world.

The CureDuchenne Professional Education Program

The CureDuchenne Professional Education Program offers both Physical Therapy (PT) and Occupational Therapy (OT) Certification specifically for Duchenne care. This unique program is designed to enhance quality of life and independence for individuals with Duchenne, focusing on prolonging mobility and slowing disease progression.

WHAT MAKES IT UNIQUE

- Only program offering certified training tailored specifically to Duchenne care
- Focuses on evidence-based interventions proven effective for progressive neuromuscular disease
- Teaches therapists to adapt approaches as disease progresses
- Emphasizes maintaining function and quality of life
- Provides ongoing education and support to certified professionals

215
Physical and occupational therapists educated in 2025 in online and in-person courses

1,900+
Course attendees since the program's inception

The Professional Education Team

Doug Levine, PT
Physical Therapist

Jennifer Wallace, PT
Physical Therapist

Improving Care Worldwide

Our global impact is driven by strategy, not one-size-fits-all solutions. From regional conferences and digital campaigns to healthcare provider training and meetings with government agencies, we tailor our outreach to meet each community's most urgent needs. Wherever families are, we bring the right resources, at the right time, to raise the standard of care worldwide. Educational programs have been provided both in-person and virtually in diverse countries, including:

NORTH AMERICA
United States
Canada
Mexico

EUROPE
England
Italy
Hungary
Ukraine
Russia

ASIA
India
Nepal
China

AFRICA
Uganda

OCEANIA
Australia

CHINA

In 2025, CureDuchenne partnered with the Chinese Organization for Rare Disorders to deliver expert-led workshops in Beijing, Shijiazhuang and Jinan, equipping hundreds of families and healthcare professionals with practical tools to improve care. This targeted approach helps close the gap between urban and rural regions, bringing lasting impact to individuals across China.

MEXICO

In 2025, CureDuchenne hosted CureDuchenne FUERZA 2025, a landmark bilingual event uniting 400 participants across 10 countries. Held in Mexico City and online, it delivered expert-led sessions on care, research, and daily life. The conference bridged language and geographic barriers to support and empower the Spanish-speaking Duchenne and Becker muscular dystrophy community.

NEPAL

In 2025, CureDuchenne partnered with Medharma Clinix Hospital to catalyze meaningful progress in Duchenne awareness and care across Nepal. Through a targeted, social media–driven education effort, the collaboration addressed a profound lack of public awareness that leaves many individuals undiagnosed and without access to appropriate care. The initiative helped bridge critical gaps in knowledge, support earlier diagnosis, and strengthen Duchenne care in the region.

850+
Healthcare providers and families reached in-person during 2025 programs

- Countless more reached through social media awareness campaign partnerships
- Training adapted to local healthcare systems and resources
- Building sustainable networks of Duchenne expertise worldwide

From Research to Care

In 2025, CureDuchenne expanded its clinical footprint with two thriving centers of excellence. These clinics reflect the full arc of CureDuchenne's mission: transforming early-stage research into real-world impact, delivered by trained experts in communities that need it most. From advanced gene therapies to bilingual support services, both clinics are bridging critical care gaps while building models of equity, innovation, and patient-centered delivery. This is what it looks like when research becomes real-world care.

CureDuchenne Clinic Opens at Rady Children's Health Orange County

We formed a landmark partnership with Rady Children's Health to establish the CureDuchenne Clinic within the Neuromuscular Program at Rady Children's Health Orange County. This clinic will provide:

- Multidisciplinary care: neurology, cardiology, pulmonology, physical/occupational therapy, nutrition, and more
- Access to next-generation diagnostics for earlier and more precise disease monitoring
- Delivery site for advanced gene therapies and emerging treatments via new Outpatient Infusion Center
- Increased engagement in clinical trials and clinical research
- Community engagement with emphasis on groups with historically disparate access to care and who are typically underrepresented in clinical research
- Creating a national model for adult transition care in partnership with University of California, Irvine

"This clinic exemplifies the power of collaboration in advancing innovative, patient-centered care for those living with Duchenne and Becker muscular dystrophy."

—Dr. John Crawford, medical director, neurology, and co-medical director, Neuroscience Institute at Rady Children's Health Orange County

The CureDuchenne Clinic in Texas Meets Growing Needs

In 2025, the CureDuchenne Clinic at the Neurology & Neuromuscular Care Center, led by renowned neurologist Dr. Diana Castro, provided care to 184 individuals living with Duchenne. As demand continues to rise, the clinic has become a vital resource for families across Texas and beyond.

With services offered in both English and Spanish, and a commitment to never turning patients away due to lack of insurance, the Dallas-based clinic is filling a critical gap in the state with the highest percentage of uninsured residents. By combining medical excellence with compassion and accessibility, the CureDuchenne Clinic is setting a new standard for what inclusive, community-centered care can look like.

"We are forever grateful for the CureDuchenne Clinic and Dr. Castro. Knowing our son is under the care of an incredibly dedicated and talented neuromuscular specialist allows us to breathe a little easier when it comes to his care."

—Rosalia Sandoval, mother of 8-year-old Joe

Building Community

Connecting Families, Building Hope

No one should face Duchenne alone. Families navigating this diagnosis need more than medical information. They need connection, understanding, and the support of others who truly know this journey. Through conferences, workshops, and virtual gatherings, CureDuchenne creates spaces where the Duchenne family community comes together to learn, share, and find hope in one another.

CureDuchenne FUTURES National Conference

MAY 22-25, 2025
San Antonio, TX

The CureDuchenne FUTURES National Conference is our annual cornerstone event bringing education, connection, and hope to the entire Duchenne community. Under the theme "Together We Thrive," the 2025 conference brought together leading scientists, clinicians, families, caregivers, and advocates for four days of learning and community building.

SESSIONS FOR EVERY NEED

- Latest research breakthroughs from portfolio companies
- Clinical care updates and standards of care
- Newly diagnosed family orientation
- Single parent support
- Sibling sessions
- Adults with Duchenne programming
- Behavioral health resources

"I love FUTURES because it's not just about learning. It's about laughing, hanging out, and being with people who really get me. It's a place where I can just be myself."

—Josh (Turbo), Age 18

698
Total attendees (661 in-person and 37 virtual)

41
Families received travel assistance (111 individuals)

37
Educational sessions covering research updates, clinical care, family support

12
Countries represented

BRINGING CARE AND CONNECTION TO COMMUNITIES

Duchenne Family Workshops & Dinner Sessions

In 2025, CureDuchenne met families where they are by bringing hands-on education and emotional support directly into communities across the country. Through a series of free regional workshops and intimate dinner sessions, families impacted by Duchenne and Becker muscular dystrophy found new opportunities to learn, connect, and feel supported.

Workshops offered full-day, in-person experiences designed to improve quality of life for individuals living with Duchenne and Becker. These interactive events included presentations from guest speakers and medical experts, access to local resources through an "open house" format, and discussions spanning multiple areas of care. Just as importantly, they created space for families to connect with others navigating similar challenges in their region.

Dinner Sessions provided a more casual but equally powerful experience. In these smaller gatherings, families came together to share stories, discuss health and wellness challenges, explore coping strategies, and talk openly about the realities of living with Duchenne, all in a welcoming and supportive environment.

257
Individuals attended family workshops

146
Individuals attended dinner sessions

18
Cities across the United States

When Gaming Communities Change the World

In 2025, the gaming world united to honor one person's legacy and change thousands of lives. Inspired by the late Mats Steen and the award-winning Netflix documentary *The Remarkable Life of Ibelin*, Blizzard Entertainment® and their massively multiplayer online role-playing game, World of Warcraft®, launched a campaign that raised an impressive $2 million for CureDuchenne's research and care programs for individuals affected by Duchenne muscular dystrophy.

MATS' STORY

Mats Steen, a Norwegian World of Warcraft player known in-game as Ibelin, was diagnosed with Duchenne as a young boy and lost his battle with the disease at age 25. His family believed he had lived in isolation until after his death, when they discovered that through World of Warcraft, Mats had built a rich world of friendships and made tremendous impacts on countless lives. His digital life was full, meaningful, and deeply connected.

THE CAMPAIGN

World of Warcraft players honored Mats' legacy by adopting a limited-edition pet fox with 100% of proceeds* supporting CureDuchenne's mission. The global gaming community rallied with unprecedented enthusiasm, making this one of the most successful charity collaborations in World of Warcraft's 20-year history, reaching millions who had never heard of Duchenne.

THE IMPACT

The $2 million raised will accelerate research toward a cure and support care programs worldwide. With millions reached through World of Warcraft and global media coverage, the campaign also introduced an entirely new audience to the realities of Duchenne muscular dystrophy. It also demonstrated the extraordinary power of community, proving that even virtual worlds can create real-world change for individuals and families living with Duchenne.

**Blizzard Entertainment donated 100% of the purchase price of "The Raven Pack" to CureDuchenne, less any chargebacks, refunds, transaction fees, and VAT or other similar taxes paid.*





$2M
Total raised

"I'm greatly humbled by the kindness of the World of Warcraft community. Their generosity in supporting CureDuchenne will help enable their incredible work and honors the deeply impactful life lived by Mats Steen."

—Holly Longdale, Executive Producer, World of Warcraft

The Fundraising That Fuels Our Impact

Learn more

The CureDuchenne Golf Shootout

Hosted by Anaheim Ducks All-Star Troy Terry and his wife Dani, this event brought together professional athletes, celebrities, and community leaders, raising $559,000 for Duchenne research and care programs. Started by NHL All-Star Ryan Getzlaf and his wife Paige 14 years ago, the Golf Shootout has been a cornerstone of CureDuchenne fundraising.

SEPTEMBER 12-13, 2025 | *Monarch Beach Golf Links, Dana Point, CA*

$559K
Total raised in 2025

$6.8M
Raised to date

"We are proud to support a cause that is so important to us and will make an impact on thousands of families facing Duchenne."

—Troy Terry, Anaheim Ducks player

The Napa Wine Series Legacy

What started in 2015 as a single event has grown into the Napa Wine Series, bringing the finest Napa Valley wines to cities across America. These distinguished events feature grand tastings and vintner-hosted dinners curated by renowned chefs. Over 11 years, Napa Wine Series events have raised more than $15.7 million for CureDuchenne.

Napa in Newport: 11 Years of Excellence

MARCH 1, 2025

Pendry Newport Beach
Newport Beach, CA

Napa in Newport returned for its 11th anniversary, bringing together 26 world-class Napa Valley vintners and philanthropists for an unforgettable evening supporting Duchenne research and care. The event featured a gourmet dinner by celebrated Chef Philip Tessier and was hosted by Vintner Chairs Luc and Jodie Morlet of Morlet Family Vineyards. At the event, CureDuchenne announced the opening of the CureDuchenne Clinic within Rady Children's Health Orange County, a groundbreaking partnership highlighting how supporters' generosity funds research, research creates therapies, and now those therapies will be delivered in a clinic their support made possible.

$1.1M
Total raised in 2025

$15M
Raised to date

"By joining forces with CureDuchenne, we are not only celebrating the art of winemaking; we are helping to fuel a mission that offers hope and support to those affected by this disease."

—Luc and Jodie Morlet, Morlet Family Vineyards

Napa in Miami: A Toast to Progress

APRIL 5, 2025 | ***Mandarin Oriental, Miami, Florida***

Napa in Miami brought together Miami's philanthropic community and wine enthusiasts as Napa Valley vintners shared their finest wines against Miami's waterfront backdrop. The success demonstrates the universal appeal of combining exceptional wine with meaningful purpose, uniting people across the country.

$680K
Total raised in 2025

Learn more

Ladies Luncheon Newport Beach

OCTOBER 14, 2025

Shady Canyon Golf Club
Irvine, California

Guests enjoyed a luxury fashion presentation by Max Mara South Coast Plaza and a gourmet lunch with wine pairings from Simon Family Estate, a boutique Napa Valley winery. Beyond the elegance, attendees heard from individuals impacted by Duchenne and gained insights into groundbreaking research.

$118K

Total raised in 2025

"CureDuchenne isn't just an organization—it's a movement. Their team of scientists, physicians, physical therapists, and advocates are working relentlessly to fund research, push for approvals, and bring real treatments to families like ours."

—Luci Nilson, mother of 16-year-old Henry, speaking at Ladies Luncheon Newport Beach

CHAMPIONS OF CHANGE

Driving Progress for Duchenne

CureDuchenne Champions and community partners continue to host impactful fundraising events, both big and small, across the country to support CureDuchenne's mission. From community gatherings to large-scale galas, these efforts fuel progress in advancing research and care.

17

Champion-led events held across the United States

$1.5M

Total raised in 2025

$422,000 RAISED

16th Annual Champions to CureDuchenne

Austin, TX

$214,000 RAISED

Champions in Dallas

Dallas, TX

$380,000 RAISED

Champions in Philadelphia Bollywood Blingo

Philadelphia, PA

$135,000 RAISED

Calves to Cure

Billings, MT

$161,000 RAISED

Dealing for Duchenne

San Antonio, TX

$152,000 RAISED

Ladies Luncheon Austin

Austin, TX

$2,000 RAISED

Hunter's Heart 5K

Los Angeles, CA

$4,000 RAISED

Cali-RAD (Reggae Against Duchenne)

San Diego, CA

$17,000 RAISED

Sawyer's Rhode to the Cure Quizzo

Township of Haddon, NJ

$17,000 RAISED

Scott's Striders Meat Raffle Fundraiser

Warsaw, NY

Partners in the Mission

CureDuchenne is honored to be selected as a beneficiary organization for charitable events that share our commitment to making a difference. These partnerships extend our reach, introduce new audiences to Duchenne, and generate significant funding for research and care.

$1,960,000 RAISED

Mack, Jack & McConaughey

Mack, Jack & McConaughey (MJ&M) is a philanthropic event founded by Mack Brown, Jack Ingram, and Matthew McConaughey, dedicated to empowering children through education, health, and wellness initiatives. CureDuchenne is honored to be a beneficiary of this high-profile Austin event, which brings together celebrities, athletes, and philanthropists for an evening of entertainment and impact.

$20,000 RAISED

Knoxville Brewfest

Knoxville Brewfest is an annual celebration of craft beer in downtown Knoxville. Over the past 14 years, the event has raised nearly $250,000, supporting research and care for individuals with Duchenne muscular dystrophy.

$22,000 RAISED

Austin Marathon

In February 2025, Tim Revell laced up his running shoes for the 20th consecutive time at the Austin Marathon, inspired by his two sons with Duchenne. Every step of the 26.2 miles—now totaling 2 million steps across his marathon runs —is a testament to his commitment to finding a cure for his sons and other boys facing Duchenne.

Be a part of the cure.
GIVE TODAY!
cureduchenne.org/donate

Financials & Impact Reports
cureduchenne.org/reports-and-financials

CureDuchenne.org | 949.872.2552 | info@cureduchenne.org
100 Bayview Cir, Suite 5600, Newport Beach, CA 92660
Federal 501(c)(3) | Tax ID: 20-0299958